Monopar Therapeutics Stock Earnings Per Share
| MNPR Stock | USD 0.73 0.07 10.18% |
Monopar Therapeutics fundamentals help investors to digest information that contributes to Monopar Therapeutics' financial success or failures. It also enables traders to predict the movement of Monopar Stock. The fundamental analysis module provides a way to measure Monopar Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Monopar Therapeutics stock.
Monopar | Earnings Per Share |
Monopar Therapeutics Company Earnings Per Share Analysis
Monopar Therapeutics' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Monopar Therapeutics Earnings Per Share | (0.61) X |
Most of Monopar Therapeutics' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Monopar Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Monopar Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for Monopar Therapeutics is extremely important. It helps to project a fair market value of Monopar Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Monopar Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Monopar Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Monopar Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
Monopar Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, Monopar Therapeutics has an Earnings Per Share of -0.61 times. This is 107.29% lower than that of the Biotechnology sector and 87.27% lower than that of the Health Care industry. The earnings per share for all United States stocks is 119.55% higher than that of the company.
Monopar Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Monopar Therapeutics' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Monopar Therapeutics could also be used in its relative valuation, which is a method of valuing Monopar Therapeutics by comparing valuation metrics of similar companies.Monopar Therapeutics is currently under evaluation in earnings per share category among related companies.
Monopar Fundamentals
| Return On Equity | -1.07 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 4.25 M | ||||
| Shares Outstanding | 17.45 M | ||||
| Shares Owned By Insiders | 52.35 % | ||||
| Shares Owned By Institutions | 1.55 % | ||||
| Number Of Shares Shorted | 150.01 K | ||||
| Price To Earning | (35.82) X | ||||
| Price To Book | 2.44 X | ||||
| EBITDA | (8.83 M) | ||||
| Net Income | (8.4 M) | ||||
| Cash And Equivalents | 16.46 M | ||||
| Cash Per Share | 1.29 X | ||||
| Total Debt | 8.41 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 7.61 X | ||||
| Book Value Per Share | 0.38 X | ||||
| Cash Flow From Operations | (7.86 M) | ||||
| Short Ratio | 0.60 X | ||||
| Earnings Per Share | (0.61) X | ||||
| Target Price | 2.0 | ||||
| Beta | 1.2 | ||||
| Market Capitalization | 11.52 M | ||||
| Total Asset | 7.35 M | ||||
| Retained Earnings | (60.21 M) | ||||
| Working Capital | 5.58 M | ||||
| Current Asset | 11.55 M | ||||
| Current Liabilities | 598.26 K | ||||
| Net Asset | 7.35 M |
About Monopar Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Monopar Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Monopar Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Monopar Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Monopar Therapeutics Piotroski F Score and Monopar Therapeutics Altman Z Score analysis. To learn how to invest in Monopar Stock, please use our How to Invest in Monopar Therapeutics guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Monopar Stock analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Monopar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monopar Therapeutics. If investors know Monopar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monopar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.61) | Return On Assets (0.54) | Return On Equity (1.07) |
The market value of Monopar Therapeutics is measured differently than its book value, which is the value of Monopar that is recorded on the company's balance sheet. Investors also form their own opinion of Monopar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Monopar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monopar Therapeutics' market value can be influenced by many factors that don't directly affect Monopar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monopar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Monopar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monopar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.